185 related articles for article (PubMed ID: 27811360)
1. p16INK4a suppresses BRCA1-deficient mammary tumorigenesis.
Scott A; Bai F; Chan HL; Liu S; Ma J; Slingerland JM; Robbins DJ; Capobianco AJ; Pei XH
Oncotarget; 2016 Dec; 7(51):84496-84507. PubMed ID: 27811360
[TBL] [Abstract][Full Text] [Related]
2. Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Wang C; Bai F; Zhang LH; Scott A; Li E; Pei XH
Breast Cancer Res; 2018 Jul; 20(1):74. PubMed ID: 29996906
[TBL] [Abstract][Full Text] [Related]
3. p16 loss rescues functional decline of Brca1-deficient mammary stem cells.
Scott A; Bai F; Chan HL; Liu S; Slingerland JM; Robbins DJ; Capobianco AJ; Pei XH
Cell Cycle; 2017 Apr; 16(8):759-764. PubMed ID: 28278054
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
Bai F; Chan HL; Scott A; Smith MD; Fan C; Herschkowitz JI; Perou CM; Livingstone AS; Robbins DJ; Capobianco AJ; Pei XH
Cancer Res; 2014 Nov; 74(21):6161-72. PubMed ID: 25239453
[TBL] [Abstract][Full Text] [Related]
5. PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors.
Bai F; Liu S; Liu X; Hollern DP; Scott A; Wang C; Zhang L; Fan C; Fu L; Perou CM; Zhu WG; Pei XH
Breast Cancer Res; 2021 Jan; 23(1):10. PubMed ID: 33478572
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing.
Sun H; Zeng J; Miao Z; Lei KC; Huang C; Hu L; Su SM; Chan UI; Miao K; Zhang X; Zhang A; Guo S; Chen S; Meng Y; Deng M; Hao W; Lei H; Lin Y; Yang Z; Tang D; Wong KH; Zhang XD; Xu X; Deng CX
Theranostics; 2021; 11(20):9967-9987. PubMed ID: 34815798
[No Abstract] [Full Text] [Related]
7. Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathway.
Bai F; Wang C; Liu X; Hollern D; Liu S; Fan C; Liu C; Ren S; Herschkowitz JI; Zhu WG; Pei XH
Cell Death Dis; 2022 Mar; 13(3):195. PubMed ID: 35236825
[TBL] [Abstract][Full Text] [Related]
8. p18INK4C and BRCA1 inhibit follicular cell proliferation and dedifferentiation in thyroid cancer.
Bai F; Liu X; Zhang X; Mao Z; Wen H; Ma J; Pei XH
Cell Cycle; 2023 Jul; 22(13):1637-1653. PubMed ID: 37345432
[TBL] [Abstract][Full Text] [Related]
9. GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
Bai F; Zhang LH; Liu X; Wang C; Zheng C; Sun J; Li M; Zhu WG; Pei XH
Theranostics; 2021; 11(17):8218-8233. PubMed ID: 34373738
[No Abstract] [Full Text] [Related]
10. Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion.
Faraldo MM; Romagnoli M; Wallon L; Dubus P; Deugnier MA; Fre S
Breast Cancer Res; 2024 Jun; 26(1):91. PubMed ID: 38835038
[TBL] [Abstract][Full Text] [Related]
11. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
[TBL] [Abstract][Full Text] [Related]
12. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation.
Brenner AJ; Stampfer MR; Aldaz CM
Oncogene; 1998 Jul; 17(2):199-205. PubMed ID: 9674704
[TBL] [Abstract][Full Text] [Related]
13. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.
Brodie SG; Xu X; Qiao W; Li WM; Cao L; Deng CX
Oncogene; 2001 Nov; 20(51):7514-23. PubMed ID: 11709723
[TBL] [Abstract][Full Text] [Related]
14. Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice.
Zhang D; Shimizu T; Araki N; Hirota T; Yoshie M; Ogawa K; Nakagata N; Takeya M; Saya H
Oncogene; 2008 Jul; 27(31):4305-14. PubMed ID: 18372918
[TBL] [Abstract][Full Text] [Related]
15. EZH2 Is Overexpressed in
Puppe J; Opdam M; Schouten PC; Jóźwiak K; Lips E; Severson T; van de Ven M; Brambillasca C; Bouwman P; van Tellingen O; Bernards R; Wesseling J; Eichler C; Thangarajah F; Malter W; Pandey GK; Ozretić L; Caldas C; van Lohuizen M; Hauptmann M; Rhiem K; Hahnen E; Reinhardt HC; Büttner R; Mallmann P; Schömig-Markiefka B; Schmutzler R; Linn S; Jonkers J
Clin Cancer Res; 2019 Jul; 25(14):4351-4362. PubMed ID: 31036541
[TBL] [Abstract][Full Text] [Related]
16. Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.
Bai F; Smith MD; Chan HL; Pei XH
Oncogene; 2013 May; 32(22):2715-25. PubMed ID: 22777348
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis.
Sarkisian CJ; Keister BA; Stairs DB; Boxer RB; Moody SE; Chodosh LA
Nat Cell Biol; 2007 May; 9(5):493-505. PubMed ID: 17450133
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma.
Matsuda Y
World J Gastroenterol; 2008 Mar; 14(11):1734-40. PubMed ID: 18350604
[TBL] [Abstract][Full Text] [Related]
19. A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.
Triplett AA; Montagna C; Wagner KU
Neoplasia; 2008 Dec; 10(12):1325-34. PubMed ID: 19048111
[TBL] [Abstract][Full Text] [Related]
20. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.
Xu X; Wagner KU; Larson D; Weaver Z; Li C; Ried T; Hennighausen L; Wynshaw-Boris A; Deng CX
Nat Genet; 1999 May; 22(1):37-43. PubMed ID: 10319859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
